Prime Medicine, Inc. (PRME)

NASDAQ: PRME · IEX Real-Time Price · USD
16.50
-0.69 (-4.01%)
Dec 1, 2022 4:00 PM EST - Market closed
-4.01%
Market Cap 1.67B
Revenue (ttm) n/a
Net Income (ttm) -157.75M
Shares Out 22.23M
EPS (ttm) -7.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 118,743
Open 17.36
Previous Close 17.19
Day's Range 16.46 - 17.55
52-Week Range 14.52 - 21.73
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About PRME

Prime Medicine is a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. We believe our in-licensed and company-owned Prime Editing technology has transformative potential that could change the course of how disease is treated and overcome the challenges associated with current genetic therapies. Prim... [Read more]

Industry Biotechnology
IPO Date Oct 20, 2022
CEO Keith Gottesdiener, M.D.
Employees 137
Stock Exchange NASDAQ
Ticker Symbol PRME
Full Company Profile

News

Prime Medicine Announces Closing of Upsized Initial Public Offering

CAMBRIDGE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies...

1 month ago - GlobeNewsWire

Is Prime Medicine (PRME) Stock the Next Hot IPO?

Prime Medicine (NASDAQ: PRME ) stock is catching the interest of traders on Thursday as the company launches its initial public offering (IPO) today! The company is launching an upsized offering that in...

1 month ago - InvestorPlace

Prime Medicine Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass.

1 month ago - Business Wire

Prime Medicine sets IPO terms, which could value the biotech at up to $1.7 billion

Prime Medicine Inc. PRME, has set terms for its initial public offering, in which the Massachusetts-based biotechnology company, which utilizes gene-editing technology to develop therapies for a wide sp...

1 month ago - Market Watch